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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract MicroRNAs (miRNAs) are short noncoding RNA molecules involved in the regulation
of carcinogenesis. Tumor-derived miRNAs will be released into the circulation, and these miR-
NAs, also known as circulating miRNAs, have stable properties in plasma and serum. Thus miR-
NAs have been suggested as a potential biomarker for cancer diagnosis. The aim of this study
was to develop a miRNA biochip platform. First, we used three types of reverse transcription
(RT) primers; we constructed the miRNA-containing poly(A) tail and used RT primer oligo(dT)
to make the complementary DNA (cDNA), and we also designed a linear-form RT primer and a
stem-loop RT primer to synthesize cDNA. Second, we selected 11 candidate miRNAs related to
colorectal cancer (CRC) from our previous studies and then designed the probes based on the
sequence of the candidate miRNAs and constructed a miRNA biochip. miRNAs were extracted
from CRC cell line SW620 and were detected by enzymatic biochip assay. According to the re-
sults, we found that this miRNA biochip can effectively detect the miRNAs by using a specific
stem-loop RT primer to synthesize cDNA. In the future, we will design more oligonucleotides
for miRNA detection and also evaluate the consistency between the results of the miRNA
biochip and quantitative real-time polymerase chain reaction (PCR).
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
MicroRNAs (miRNAs) can regulate many cellular functions,
including cell growth, cell differentiation, cell metabolism,f Medical Research, Fooyin
shan Road, Donggang Town-
il.com (J.-Y. Chang).
4.08.009
Genomic Medicine and Biomarkerand cell death. miRNAs are small fragments, 20e23 nucle-
otide (nt) single strands of endogenous RNA, that play
important gene-regulatory roles in animals and plants by
pairing to the messenger RNAs (mRNAs) of protein-coding
genes to direct their posttranscriptional repression.1 miR-
NAs are largely conserved between species, implying that
their gene regulatory function may have ancient origins.
Currently, >1000 human miRNA sequences are known, and
it has been speculated that miRNA could regulate approx-
imately 60% of the human genome.2 The binding of miRNASociety. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 We designed 11 microRNA (miRNA) reverse tran-
scription (RT) primers with a stem-loop structure that is easier
to combine with miRNA for complementary DNA (cDNA) syn-
thesis. Then, cDNA was labeled with biotin for miRNA biochip
hybridization.
miRNA biochip platform 155to mRNA results in a reduced translation rate or increased
degradation of the mRNA. Alterations in miRNA expression
are observed in many different human diseases, including
cancer. Genetic and epigenetic alterations may explain
aberrant miRNA expression in cancer cells and may also
contribute to cancer risk. Abnormal miRNA expression,
including the absence, amplification, mutation, or epige-
netic silencing of miRNA, can cause cancer.3,4
In 2008, Chim et al5 used the quantitative reverse
transcription polymerase chain reaction (qRT-PCR) tech-
nique to find that miRNA is expressed in plasma, proving the
presence of circulating miRNA for the first time. Lawrie
et al6 also found miR-155, miR-210, and miR-21 over-
expression in diffuse large B-cell lymphoma plasma, and
further found that overexpression of miR-21 is related to
relapse-free survival. Furthermore, the circulating miRNAs
are more stable in blood because miRNAs can be easily
stored in difficult environments (such as those with
extreme pH values and high temperatures).7e9 Many studies
have also pointed out that circulating miRNA can serve as a
biomarker for diagnosis in cases of breast cancer,10,11 lung
cancer,12,13 and gastric cancer.14
Nowadays, there are three major methods for analyzing
miRNA, qRT-PCR assays, microarray column (microarray)
assays, and the next-generation sequencing (NGS) method.
In qRT-PCR, analyzing a single biomarker only provides
limited sensitivity and specificity, while microarray and NGS
analyses are time-consuming and expensive and cannot be
widely used in clinical work. In this study, therefore, our
aim was to develop a miRNA biochip platform that can
analyze multiple targets simultaneously and that is inex-
pensive and easy to operate.
Materials and methods
Cell culture
We used the human colon cancer cell line SW620 [Union for
International Cancer Control (UICC) stage III] (ATCC CCL-
227; American Type Culture Collection, Manassas, VA,
USA) in this study. We maintained the cells with Leibovitz’s
L-15 medium which contains 10% fetal bovine serum (Bio-
logical Industries Israel Beit-Haemek Ltd, Kibbutz BeitTable 1 Oligonucleotide sequences for the reverse transcriptio
MicroRNA (miRNA) name RT prim
hsa-miR-494 TTGGAG
hsa-miR-4722-3p GACGTC
hsa-miR-1283 GAAAGA
hsa-miR-3925-5p CTCGG
hsa-miR-3150a-3p CCAACC
hsa-miR-450b-5p ACTTAT
hsa-miR-548ah-5p ACAAAC
hsa-miR-4495 CGTGAG
hsa-miR-875-3p CAACAC
hsa-miR-493-5p AAGTAA
hsa-miR-361-5p CCCATG
hsa-miR-3613-3p GGGAA
hsa-miR-145-5p TAGGGHaemek, Israel), and added Penicillin-Streptomycin Solu-
tion (Biological Industries Israel Beit-Haemek Ltd, Kibbutz
Beit Haemek, Israel) to avoid contamination. SW620 cells
were cultured in T-25 flasks, and incubated at 37C withoutn (RT) primers.
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Figure 2 (A) A schematic of the microRNA (miRNA) biochip. (BeD) We used three types of reverse transcription (RT) primer, (B) a
miRNA-containing poly(A) tail and RT primer oligo(dT), (C) specific linear RT primers, and (D) a specific stem-loop RT primer, to
synthesize the complementary DNA (cDNA) that hybridized with the miRNA biochip. (EeG) The results of the miRNA biochip using
three different concentrations of the specific stem-loop RT primer: (E) 10 mM; (F) 1 mM; and (G) 0.1 mM. Blue squares represent
positive control (PC), green squares represent negative control (NC), and red squares represent the target miRNAs. 1 Z hsa-miR-
4722-3p gene; 2 Z hsa-miR-145-5p gene.
156 J.-Y. Chang et al.5% CO2 (Thermo Scientific Forma 310 Direct-Heat CO2;
Thermo Fisher Scientific Inc, Waltham, MA, USA).miRNA extraction
We extracted miRNA from the SW620 cells. We used a
mirVana PARIS kit (Ambion, Foster, CA, USA), following the
instructions in the operating manual, to isolate the miRNAs.Design of RT primer
We selected candidate miRNA genes related to colorectal
cancer (CRC) according to our previous studies in which we
used microarray to compare the gene expressions between
CRC tumor tissues and normal tissues.15,16 Then, we used the
software miRDB (http://mirdb.org/miRDB/index.html) and
microRNA.org (http://www.microrna.org/microrna/home.
do) to predict the miRNA for the CRC-specific genes. In
miRNA biochip platform 157order to reverse miRNA to complementary DNA (cDNA), we
tried using three types of RT primers to form cDNA. First, we
used the Poly(A) Polymerase Tailing Kit (Epicentre, Madison,
WI, USA) for the rapid and efficient addition of poly(A)-tails
to the 30 end of RNA. Poly(A)-tails can provide priming sites
for the synthesis of first-strand cDNA, so we constructed the
miRNA-containing poly(A) tail and used RT primer oligo(dT)
(SIGMA-ALDRICH, St. Louis, MO, USA) to make the cDNA.
Second, we constructed a specific RT primer (linear form) for
the target miRNA to synthesize cDNA (data not shown). Ac-
cording to previous studies, a specific RT stem-loop form
primer can bind well with miRNA to synthesize the cDNA.17
Thus, we designed a specific RT primer sequence to be a
stem-loop form for the target miRNA to enable the synthesis
of cDNA (Table 1).
Construction of miRNA biochip
We designed 18 oligonucleotide probes for 11 miRNA se-
quences (5 of 11 miRNAs were designed using 2 different
sequences) and two positive control sequences, and used
an AD1500 Dispensing System (BioDot Inc., Irvine CA, USA)
to construct a miRNA biochip. The concentrations of the
newly synthesized oligonucleotide fragments for each spot
were 100 mM, and there was a distance of 1.5 mm between
spots on a nylon membrane in triplicate. After rapid drying
and cross-linking procedures, the miRNA biochip was
completed and stored in a dry oven.
Enzymatic biochip assay
We applied first-strand cDNA for biotin labeling to synthe-
size the biotin-labeled probes. The probes were then hy-
bridized with the miRNA biochip and incubated for 6e17
hours at 100 revolutions per minute (rpm) at 42C. Then the
hybridized chips were subjected to washing, blocking, and
color development procedures using a GeneCling Enzymatic
Gene Chip Detection Kit (Carygene Biotechnology Company
Ltd, Kaohsiung, Taiwan). The miRNA biochip assays were
scanned with a Microtek ScanMaker s460 scanner (Microtek
International Inc., Hsinchu, Taiwan).
Results
We used three methods to convert miRNA to cDNA,
including using a miRNA-containing poly(A) tail and RT
primer oligo(dT), using specific linear RT primers, and using
a specific stem-loop RT primer (Fig. 1). Then, the gene
expressions of miRNAs were analyzed by the miRNA biochip
platform (Fig. 2A). The procedure involved in using a spe-
cific stem-loop RT primer sequence to synthesize cDNA was
workable through biochip assays (Fig. 2B and D). Two target
miRNA genes, hsa-miR-4722-3p and hsa-miR-145-5p, were
successfully detected using this miRNA biochip with 10 mM
primer; only hsa-miR-4722-3p could be detected using 1 mM
primer (Fig. 2EeG).
Discussion
In a recent study, markers of circulating tumor cells (CTCs)
in the peripheral blood of CRC patients were found to bepotentially useful for cancer diagnosis.18 The techniques
commonly used for detecting CTCs are PCR, RT-PCR, or real-
time quantitative PCR (RT-qPCR) assays. The enzymatic
gene chip array platform that we developed in our previous
study can detect CTCs in the peripheral blood of CRC pa-
tients,19 and it is highly sensitive and specific. In recent
years, many miRNAs have been found to play an important
role in the process of cell carcinoma. In 2008, it was first
demonstrated that miRNA is expressed in plasma.5 The
detection of circulating miRNA, however, has commonly
relied on techniques such as microarray assays, quantitative
real-time PCR assays, and NGS. In this study, our aim was to
develop a miRNA biochip platform as a new detection
technique to detect miRNA. As the results show, this miRNA
biochip using a specific stem-loop RT primer to synthesize
cDNA can effectively detect miRNAs. According to previous
studies, a specific RT stem-loop form primer can selectively
target mature miRNAs and obtain accurate miRNA expres-
sion data.17,20 In the future, we will design more experi-
ments to improve the sensitivity and specificity of this new
platform, and also evaluate the consistency between the
results of this miRNA biochip and those of quantitative real-
time PCR assays. Moreover, we will use different types of
samples, including blood specimens, to evaluate the sensi-
tivity of this new platform for clinical applications.
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